Maze Therapeutics (MAZE) Long-Term Investments (2025 - 2026)
Maze Therapeutics recorded quarterly Long-Term Investments of $10.6 million in Q1 2026, down 41.72% quarter-over-quarter from $18.1 million in Q4 2025.
Maze Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $10.6 million for Q1 2026.
- In Q1 2026, Long-Term Investments changed N/A year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (changed N/A YoY), while the FY2025 annual figure was $18.1 million, changed N/A from the prior year.
- Long-Term Investments came in at $10.6 million for Q1 2026 at Maze Therapeutics, down from $18.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $18.1 million in Q4 2025 to a low of $10.6 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | 10.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 18.11 Mn |